Should You Chase the Rally in Alumis Stock Today?

Alumis (ALMS) stock exploded higher on Tuesday after the biotech firm reported promising Phase 3 results for envudeucitinib, its candidate treatment for psoriasis. In the late-stage trial, envudeucitinib helped patients experience symptom improvement that “rank among the strongest reported for an oral therapy,” the company said in its press release. More News from Barchart While ALMS shares reversed nearly half of their intraday gains by market close on Jan. 6, at one point, they were seen trading at a ...